GM2 Gangliosidosis Quantitative Blood Test (Tay-Sachs & Sandhoff Disease) in UAE | 550 AED | 2026 DHA Guidelines

Q1: What exactly does the GM2 Gangliosidosis Quantitative Blood Test measure, and who should get tested?

This test quantitatively measures hexosaminidase A and total hexosaminidase enzyme activity levels in whole blood to definitively diagnose Tay-Sachs and Sandhoff disease. The is recommended for infants and children presenting with developmental regression, an exaggerated startle response to sound, cherry-red spots on retinal examination, progressive muscle weakness, or macrocephaly — all hallmark signs prompting urgent pediatric neurological evaluation. Additionally, adults with late-onset forms presenting with progressive muscle atrophy, psychiatric symptoms, or cerebellar ataxia should be tested. Carrier testing for at-risk couples of Ashkenazi Jewish, French-Canadian, Cajun, or Irish descent — populations with elevated carrier frequencies — is also clinically indicated, though in the UAE's multicultural population, physician-directed testing based on clinical suspicion remains the primary pathway.

Q2: How is the blood sample collected, and what is the turnaround time for results in UAE?

A total of 10 milliliters of whole blood is drawn across three lavender-top EDTA or green-top sodium heparin tubes via standard venipuncture. Our DHA-licensed mobile phlebotomy team performs hospital-grade home collection across all seven Emirates from 8 AM to 11 PM daily, with specimens transported under refrigerated cold-chain conditions (2°C–8°C) directly to our ISO-certified laboratory. It is absolutely critical that samples are never frozen — freezing irreversibly destroys the leukocyte enzyme activity required for accurate quantification. Samples received by 4 PM are processed the same day, and the final report is delivered within 4 working days via secure electronic portal with optional telephonic interpretation by our clinical team.

Q3: What do abnormal or low enzyme activity results mean for my child's health and future?

Abnormally low or absent hexosaminidase A activity confirms a diagnosis of Tay-Sachs disease, while deficiency of both hexosaminidase A and B confirms Sandhoff disease. These are autosomal recessive conditions, meaning both parents are obligate carriers and each subsequent pregnancy carries a 25% risk of an affected child. A confirmed diagnosis necessitates immediate referral to a multidisciplinary metabolic team including pediatric neurology, clinical genetics, ophthalmology, and palliative care specialists. While there is currently no curative treatment, early diagnosis enables optimized supportive care, seizure management, nutritional support, and access to clinical trials. Genetic counseling for the family is essential to discuss reproductive options including preimplantation genetic diagnosis (PGD) and prenatal testing for future pregnancies. Our clinical consultants are available to guide you through every step of this process with compassion and evidence-based clarity.